BackgroundCheck.run
Search For

Beth Ann Mckechnie, 7212 Wheaton Dr, South Attleboro, MA 02703

Known as:
Beth A Mckechnie Beth Ann Gurnham Beth A Mckechine Ba Mckechnie Beth A Mckecknie Beth A Mc Beth Mc Kechnie Beth Mckechinie
Related to:
Beth A Mckecknie 72

Beth Mckechnie Phones & Addresses

12 Wheaton Dr, Attleboro, MA 02703   

South Dennis, MA   

Blackstone, MA   

Northbridge, MA   

North Attleboro, MA   

Maynard, MA   

Franklin, MA   

Get Report
Control this profile

Mentions for Beth Ann Mckechnie

Beth Mckechnie resumes & CV records

Resumes

Beth Mckechnie Photo 20

Former Research Associate

Location:
Attleboro, MA
Industry:
Research
Work:
Brown University
Former Research Associate
Education:
Wheaton College Massachusetts
Bachelors, Bachelor of Arts, Biology, Psychology
Skills:
Laboratory Management, Project Management, Bioassay Development, Cell Culture, Microscopy, Qualitative Research, Fluorescence Microscopy, Biochemistry
Beth Mckechnie Photo 21

Beth Mckechnie

Publications & IP owners

Us Patents

Biglycan And Related Therapeutics And Methods Of Use

US Patent:
7335637, Feb 26, 2008
Filed:
Jun 14, 2004
Appl. No.:
10/868247
Inventors:
Justin R. Fallon - Harvard MA, US
Beth McKechnie - Franklin MA, US
Michael Rafii - Riverside RI, US
Hilliary Creely - Providence RI, US
Mark A. Bowe - Derwood MD, US
Raymond Ferri - Providence RI, US
Assignee:
Brown University Research Foundation - Providence RI
International Classification:
A61K 38/00
A61K 45/00
A61K 39/00
A01N 37/18
US Classification:
514 12, 514 2, 4242781, 4242791, 4241841, 4241851, 4241921
Abstract:
The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e. g. , to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.

Biglycan And Related Therapeutics And Methods Of Use

US Patent:
7612038, Nov 3, 2009
Filed:
Feb 20, 2002
Appl. No.:
10/081736
Inventors:
Justin R. Fallon - Harvard MA, US
Beth McKechnie - Franklin MA, US
Michael Rafii - Baltimore MD, US
Hilliary Creely - Providence RI, US
Mark A. Bowe - Damascus MD, US
Alison Amenta - Pawtucket RI, US
Mary Lynn Mercado - Robbinsville NJ, US
Hiroki Hagiwara - Tokyo, JP
Assignee:
Brown University - Providence RI
International Classification:
A61K 38/00
A61K 45/00
A61K 39/00
A01N 37/18
US Classification:
514 12, 514 2, 4242781, 4242791, 4241841, 4241851, 4241921
Abstract:
The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e. g. , to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.

Treatment Of Muscular Dystrophies And Related Disorders

US Patent:
7759314, Jul 20, 2010
Filed:
Aug 15, 2002
Appl. No.:
10/486678
Inventors:
Justin R. Fallon - Harvard MA, US
Michael Rafii - Baltimore MD, US
Alison Amenta - Pawtucket RI, US
Mark Bowe - Damasus MD, US
Beth McKechnie - Franklin MA, US
Mary Lynn Mercado - Robbinsville NJ, US
Hiroki Hagiwara - Bunkyo-Ku, JP
Assignee:
Brown University - Providence RI
International Classification:
A01N 37/18
A61K 38/00
C07K 2/00
C07K 4/00
C07K 5/00
C07K 7/00
C07K 14/00
C07K 16/00
C07K 17/00
US Classification:
514 20, 530300
Abstract:
The invention provides, among other aspects, compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; diseases or conditions associated with an abnormal level or activity of collagen VI; disorders associated with an unstable cytoplasmic membrane, due, e. g. , to an unstable dystrophin associated protein complex (DAPC); and disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation.

Biglycan And Related Therapeutics And Methods Of Use

US Patent:
7816322, Oct 19, 2010
Filed:
Feb 22, 2008
Appl. No.:
12/072008
Inventors:
Justin R. Fallon - Brooklyn CT, US
Mark A. Bowe - Damascus MD, US
Beth McKechnie - Franklin MA, US
Michael Rafii - San Diego CA, US
Alison Amenta - Pawtucket RI, US
Mary Lynn Mercado - Robbinsville NJ, US
Hiroki Hagiwara - Tokyo, JP
Assignee:
Brown University Research Foundation - Providence RI
International Classification:
A61K 38/00
A61K 45/00
A61K 39/00
A01N 37/18
US Classification:
514 12, 514 2, 4242781, 4242791, 4241841, 4241851, 4241921
Abstract:
The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e. g. , to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.

Biglycan And Related Therapeutics And Methods Of Use

US Patent:
8138154, Mar 20, 2012
Filed:
Jul 6, 2009
Appl. No.:
12/498172
Inventors:
Justin R. Fallon - Providence RI, US
Beth McKechnie - Franklin MA, US
Michael Rafii - La Jolla CA, US
Hilliary Creely - Providence RI, US
Mark A. Bowe - Damascus MD, US
Alison Amenta - Pawtucket RI, US
Mary Lynn Mercado - Robbinsville NJ, US
Hiroki Hagiwara - Tokyo, JP
Assignee:
Brown University Research Foundation - Providence RI
International Classification:
A61K 38/00
A61K 45/00
A61K 39/00
A01N 37/18
US Classification:
514 177, 514 76, 514 83, 514 165, 514 179, 4242791, 4241841, 4241851, 4241921
Abstract:
The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e. g. , to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Example of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.

Treatment Of Muscular Dystrophies And Related Disorders

US Patent:
2011005, Mar 3, 2011
Filed:
May 24, 2010
Appl. No.:
12/786294
Inventors:
Justin R. Fallon - Brooklyn CT, US
Michael Rafii - San Diego CA, US
Mark A. Bowe - Damascus MD, US
Beth McKechnie - Franklin MA, US
Alison Amenta - Pawtucket RI, US
Mary Lynn Mercado - Robbinsville NJ, US
Hiroki Hagiwara - Tokyo, JP
International Classification:
A61K 38/17
A61P 21/00
US Classification:
514 172
Abstract:
The invention provides, among other aspects, compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; diseases or conditions associated with an abnormal level or activity of collagen VI; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); and disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation.

Biglycan And Related Therapeutics And Methods Of Use

US Patent:
2011018, Jul 28, 2011
Filed:
Sep 14, 2010
Appl. No.:
12/881891
Inventors:
Justin R. Fallon - Brooklyn CT, US
Mark A. Bowe - Damascus MD, US
Beth McKechnie - Franklin MA, US
Michael Rafii - San Diego CA, US
Alison Amenta - Pawtucket RI, US
Mary Lynn Mercado - Robbinsville NJ, US
Hiroki Hagiwara - Tokyo, JP
Assignee:
Brown University Research Foundation - Providence RI
International Classification:
A61K 38/17
C12N 5/077
A61K 31/7088
A61P 21/00
US Classification:
514 177, 435325, 514 212, 514 44 R
Abstract:
The invention provides compositions and methods for treating, preventing, and diagnosing diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, due, e.g., to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.

Biglycan Mutants And Related Therapeutics And Methods Of Use

US Patent:
2012000, Jan 5, 2012
Filed:
May 17, 2011
Appl. No.:
13/109558
Inventors:
Justin R. Fallon - Providence RI, US
Alison R. Amenta - Pawtucket RI, US
Beth A. McKechnie - North Attleboro MA, US
Michelle Dechene - Providence RI, US
Atilgan Yilmaz - Providence RI, US
International Classification:
A61K 38/17
A61P 25/00
A61P 21/00
C12N 5/071
G01N 33/566
C12P 21/00
C12N 5/10
C12N 1/21
C12N 1/19
C07K 14/435
C12N 5/077
US Classification:
514 177, 530350, 514 11, 435375, 435 691, 435369, 435358, 435349, 435348, 435325, 4352523, 4352542, 435 71, 435 792
Abstract:
The present disclosure provides compositions and methods for treating diseases or conditions associated with an abnormal level or activity of biglycan; disorders associated with an unstable cytoplasmic membrane, for example, due to an unstable dystrophin associated protein complex (DAPC); disorders associated with abnormal synapses or neuromuscular junctions, including those resulting from an abnormal MuSK activation or acetylcholine receptor (AChR) aggregation. Examples of diseases include muscular dystrophies, such as Duchenne's Muscular Dystrophy, Becker's Muscular Dystrophy, neuromuscular disorders and neurological disorders.

Possible Relatives

Cynthia Mckechnie  David Mckechnie  Daniel Mckechnie  Dennis M Mckechnie  Eugene W Mckechnie  Gary L Mckechnie  Ian M Mckechnie  Beth Johnson  Beth B Standley  Beth L Stanek 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.